HC Wainwright Reiterates "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating restated by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $75.00 target price on the biotechnology company's stock. HC Wainwright's price target would suggest a potential downside of 25.90% from the company's current price.

SRPT has been the topic of several other research reports. Needham & Company LLC reissued a "buy" rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Piper Sandler lowered their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price target for the company. Finally, StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $173.52.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded down $5.53 on Thursday, hitting $101.22. 1,354,604 shares of the company traded hands, compared to its average volume of 867,510. The stock has a market capitalization of $9.67 billion, a P/E ratio of 80.98 and a beta of 0.75. Sarepta Therapeutics has a 52 week low of $100.14 and a 52 week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50-day simple moving average of $115.89 and a 200 day simple moving average of $122.46.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank lifted its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics during the fourth quarter worth $36,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.